These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8625543)

  • 1. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease.
    Sullivan KM
    Clin Exp Immunol; 1996 May; 104 Suppl 1():43-8. PubMed ID: 8625543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.
    Sullivan KM; Storek J; Kopecky KJ; Jocom J; Longton G; Flowers M; Siadak M; Nims J; Witherspoon RP; Anasetti C; Appelbaum FR; Bowden RA; Buckner CD; Crawford SW; Deeg HJ; Hansen JA; McDonald GB; Sanders JE; Storb R
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):44-53. PubMed ID: 9078354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.
    Feinstein LC; Seidel K; Jocum J; Bowden RA; Anasetti C; Deeg HJ; Flowers ME; Kansu E; Martin PJ; Nash RA; Storek J; Etzioni R; Applebaum FR; Hansen JA; Storb R; Sullivan KM
    Biol Blood Marrow Transplant; 1999; 5(6):369-78. PubMed ID: 10595814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.
    Siadak MF; Kopecky K; Sullivan KM
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):53-7. PubMed ID: 8033436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
    Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune globulin therapy in allogeneic bone marrow transplant: a critical review.
    Guglielmo BJ; Wong-Beringer A; Linker CA
    Bone Marrow Transplant; 1994 May; 13(5):499-510. PubMed ID: 8054903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation.
    Sokos DR; Berger M; Lazarus HM
    Biol Blood Marrow Transplant; 2002; 8(3):117-30. PubMed ID: 11939601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
    Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
    Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
    Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.
    Sullivan KM; Kopecky KJ; Jocom J; Fisher L; Buckner CD; Meyers JD; Counts GW; Bowden RA; Peterson FB; Witherspoon RP
    N Engl J Med; 1990 Sep; 323(11):705-12. PubMed ID: 2167452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.
    Bass EB; Powe NR; Goodman SN; Graziano SL; Griffiths RI; Kickler TS; Wingard JR
    Bone Marrow Transplant; 1993 Sep; 12(3):273-82. PubMed ID: 8241987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-host disease after marrow transplantation.
    Storb R
    Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin in bone marrow transplantation.
    Gale RP; Winston D
    Cancer; 1991 Sep; 68(6 Suppl):1451-3. PubMed ID: 1652350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marrow transplant experience for children with severe aplastic anemia.
    Sanders JE; Storb R; Anasetti C; Deeg HJ; Doney K; Sullivan KM; Witherspoon RP; Hansen J
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.